Madrigal Pharmaceuticals Inc (MDGL) has shared an announcement.
Madrigal Pharmaceuticals has announced the FDA’s accelerated approval of Rezdiffra™, a treatment for adults with a specific type of liver disease known as noncirrhotic nonalcoholic steatohepatitis (NASH) with moderate to advanced fibrosis. The approval, which could change based on results from further trials, marks a significant milestone for patients in need of new therapeutic options for this challenging condition.
Learn more about MDGL stock on TipRanks’ Stock Analysis page.
